Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion
Further Audits Will Investigate Company Practices
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.
You may also be interested in...
Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation
WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.
ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach
The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahota, has resigned from the role at the association after the company breached the ABPI's Code of Practice.
More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences
In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.